Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HDR”

129 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 129 results

Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Not applicableTemporarily pausedNCT05820633
What this trial is testing

Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.

Who this might be right for
Prostate CancerNode; ProstateRadiotherapy Side Effect
CHU de Quebec-Universite Laval 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT02849496
What this trial is testing

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable Breast Carcinoma+1 more
National Cancer Institute (NCI) 89
Testing effectiveness (Phase 2)Active Not RecruitingNCT05003752
What this trial is testing

Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer

Who this might be right for
Prostate AdenocarcinomaRadiation Toxicity
German Oncology Center, Cyprus 40
Testing effectiveness (Phase 2)Ended earlyNCT05286827
What this trial is testing

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Who this might be right for
Pancreatic Acinar Cell Carcinoma
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07005583
What this trial is testing

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital 46
Not applicableActive Not RecruitingNCT03312972
What this trial is testing

Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy

Who this might be right for
Locally Recurrent Prostate Cancer
Loyola University 50
Testing effectiveness (Phase 2)UnknownNCT01175694
What this trial is testing

Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer

Who this might be right for
Breast Cancer
University Hospital Erlangen 200
Not applicableUnknownNCT03110497
What this trial is testing

Single Application Brachytherapy in Cervical Cancer

Who this might be right for
Cervical Cancer
Tata Memorial Hospital 40
Not applicableLooking for participantsNCT07501845
What this trial is testing

Registry Maastro Applicator

Who this might be right for
Rectal Cancer
Maastricht Radiation Oncology 999
Testing effectiveness (Phase 2)WithdrawnNCT06120972
What this trial is testing

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Who this might be right for
Ovarian Cancer
Alexander B Olawaiye, MD
Large-scale testing (Phase 3)UnknownNCT04473339
What this trial is testing

Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerOvarian Cancer, Epithelial+2 more
CAI Hongbing 280
Testing effectiveness (Phase 2)Ended earlyNCT03442556
What this trial is testing

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Who this might be right for
ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+7 more
University of Washington 18
Testing effectiveness (Phase 2)WithdrawnNCT05174455
What this trial is testing

Niraparib for the Treatment of Leiomyosarcoma

Who this might be right for
Locally Advanced LeiomyosarcomaMetastatic LeiomyosarcomaStage III Retroperitoneal Sarcoma AJCC v8+4 more
David Liebner, MD
Not applicableActive Not RecruitingNCT06964412
What this trial is testing

The Use of Artificial Intelligence Generated Contours in Radiation Planning of the Prostate Brachytherapy

Who this might be right for
Prostate Cancer
Brigham and Women's Hospital 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT02422498
What this trial is testing

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Who this might be right for
Locally Recurrent/Metastatic Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center 49
Testing effectiveness (Phase 2)Looking for participantsNCT03424850
What this trial is testing

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Who this might be right for
Prostate CancerProstate Neoplasm
Washington University School of Medicine 36
Testing effectiveness (Phase 2)Study completedNCT00931775
What this trial is testing

Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder

Who this might be right for
Major Depressive DisorderAntidepressant Treatment Response
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 30
Not applicableWithdrawnNCT04645810
What this trial is testing

Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence

Who this might be right for
Prostate CancerHDR
University of Rochester
Testing effectiveness (Phase 2)Looking for participantsNCT06591819
What this trial is testing

Hypofractionated WPPT With HDR Boost

Who this might be right for
Prostate Cancer
Abramson Cancer Center at Penn Medicine 30
Next Page